sorafenib has been researched along with tiliroside in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tiliroside) | Trials (tiliroside) | Recent Studies (post-2010) (tiliroside) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 92 | 0 | 56 |
| Protein | Taxonomy | sorafenib (IC50) | tiliroside (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, D; Liu, M; Lu, T; Xu, M; Yang, C; Yuan, X; Zhang, J; Zhou, L | 1 |
1 other study(ies) available for sorafenib and tiliroside
| Article | Year |
|---|---|
Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Flavonoids; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; NF-E2-Related Factor 2; Protein Serine-Threonine Kinases; Sorafenib | 2023 |